⌘K
Loading ticker…
Moderna, Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, Moderna, Inc. Common Stock (MRNA) has a 3-month relative strength percentile of 77 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 78. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 8.4%, relative volume 1.84×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
3m RS is 77, Market Stance is mixed at 47, A/D rating B
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
MRNA is in a stage 2 uptrend, week 3. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 31.5% / 67.6%.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
MRNA is held by 16 ETFs as of Mar 2026. Top owner: VTI at 0.03% weight, $574M notional. Top 3 carry $1.4B.
Top 10 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.03% | $574M |
| VOOVanguard S&P 500 ETF | 0.03% | $449M |
| VBVanguard Small Cap ETF | 0.25% | $416M |
| VBRVanguard Small Cap Value ETF | 0.44% | $265M |
| IVViShares Core S&P 500 ETF | 0.03% | $227M |
| SPYState Street SPDR S&P 500 ETF | 0.03% | $206M |
| XLVState Street Health Care Select Sector SPDR ETF | 0.33% | $129M |
| XBIState Street SPDR S&P Biotech ETF | 1.03% | $77M |
| IWRiShares Russell Midcap ETF | 0.14% | $69M |
| IWDiShares Russell 1000 Value ETF | 0.06% | $42M |
Showing 10 of 16 ETF owners.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | MRNA Jan avg: 10.97% median: -0.19% win: 50% σ: 25.80% n: 4 2022-04-12 → 2026-05-29 | MRNA Feb avg: -7.45% median: -14.94% win: 25% σ: 20.23% n: 4 2022-04-12 → 2026-05-29 | MRNA Mar avg: 3.14% median: 2.73% win: 50% σ: 11.73% n: 4 2022-04-12 → 2026-05-29 | MRNA Apr avg: -6.97% median: -9.57% win: 40% σ: 8.64% n: 5 2022-04-12 → 2026-05-29 | MRNA May avg: 5.85% median: 2.72% win: 60% σ: 14.32% n: 5 2022-04-12 → 2026-05-29 | MRNA Jun avg: -4.85% median: -3.28% win: 25% σ: 8.69% n: 4 2022-04-12 → 2026-05-29 (current) | MRNA Jul avg: 4.81% median: 3.77% win: 75% σ: 7.95% n: 4 2022-04-12 → 2026-05-29 | MRNA Aug avg: -19.22% median: -18.95% win: 0% σ: 12.74% n: 4 2022-04-12 → 2026-05-29 | MRNA Sep avg: -6.42% median: -9.63% win: 25% σ: 9.33% n: 4 2022-04-12 → 2026-05-29 | MRNA Oct avg: -3.21% median: -6.75% win: 50% σ: 24.29% n: 4 2022-04-12 → 2026-05-29 | MRNA Nov avg: -1.46% median: -1.03% win: 50% σ: 15.68% n: 4 2022-04-12 → 2026-05-29 | MRNA Dec avg: 10.04% median: 7.81% win: 75% σ: 13.89% n: 4 2022-04-12 → 2026-05-29 |